Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaTony Mok, Masahiro Fukuoka, Yi‐Long Wu et al.|New England Journal of Medicine|2009Cited by 8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science|2007Cited by 4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Aaron S. Mansfield et al.|New England Journal of Medicine|2018Cited by 3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Michael Thomas et al.|New England Journal of Medicine|2013Cited by 3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Yi‐Long Wu et al.|The Lancet|2019Cited by 3.3k